1. Pink Sheet
  2. >>Market Access

FDA To Issue Decision On Florida’s Drug Importation Proposal By October

 
• By Brenda Sandburg

Florida was the first of four states to submit proposals for importation of prescription drugs from Canada. PhRMA recently filed a citizen petition opposing Colorado’s proposal, which notes hurdles it is facing. Infographic compares state proposals and the drugs they plan to import.

Drug importation
FDA is moving to complete reivew of Florida's proposed program to import prescription drugs from Canada • Source: Shutterstock

The US Food and Drug Administration might be close to authorizing the first state program to import prescription drugs from Canada. The agency noted in a recent court filing that it is reviewing Florida’s amended program proposal and will be issuing a decision by 31 October.

Key Takeaways

  • FDA could authorize the first two prescription drug importation proposals, from Florida and Colorado, this year.

  • Colorado's experience shows the difficulties such programs face, including the reluctance of manufacturers and pharmacies to participate in them.

  • PhRMA is continuing to fight drug importation through citizen petitions to FDA and could revive a lawsuit that was dismissed because no importation program had not gone into effect to harm companies

The agency's acceptance of the proposal would be a significant event, following years of debate over whether prescription drug importation can actually result in savings for American

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

EU HTA Regulation: ‘Stepping Beyond’ JCAs May Be Needed For Very Rare Disease Drugs

 
• By Francesca Bruce

Cooperation between health technology assessment bodies across the EU will lead to a better joint clinical assessment process over time, but patients cannot afford a lengthy wait for improvements, speakers at a cell & gene therapy conference said.

EU Pharma Reform: Exclusivity Vouchers Alone Are Insufficient Incentive For Antimicrobials, Industry Says

 
• By Eliza Slawther

European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.

Pharma Predicts Modest Tariff Impact, Depending On What Comes Next

 
• By Jessica Merrill

Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.

US FDA Not Industry’s ‘Sock Puppet,’ Ultragenyx’s Emil Kakkis Says

 
• By Sue Sutter

The biotech CEO said the Trump Administration’s treatment of FDA employees, including the HHS secretary’s comments about industry capture, are insulting to agency staff, but he is encouraged by FDA Commissioner Martin Makary’s talk of a new conditional approval pathway.

More from Pink Sheet

EU Pharma Reform: Exclusivity Vouchers Alone Are Insufficient Incentive For Antimicrobials, Industry Says

 
• By Eliza Slawther

European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.

Trump Administration Push For Dismissal, Transfer Of Mifepristone Case Leaves Overhang For Pharma

 
• By Sarah Karlin-Smith

The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.

Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling

 
• By Sue Sutter

Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.